Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963578 | 1.00 | MEN1 (0.40) | MEN1GFERKMT2AHTR6DRD2 | |
| SCHEMBL23677771 | 0.91 | MEN1 (0.39) | MEN1GFERKMT2AHTR6DRD2 | |
| SCHEMBL20530220 | 0.88 | MEN1 (0.38) | MEN1GFERKMT2AHTR6DRD2 | |
| SCHEMBL25189031 | 0.87 | POLB (0.40) | KMT2AHTR6DRD2NFE2L2POLB | |
| SCHEMBL31019968 | 0.87 | POLB (0.40) | KMT2AHTR6DRD2NFE2L2POLB | |
| SCHEMBL25313711 | 0.85 | NFE2L2 (0.35) | KMT2ASMN1; SMN2NFE2L2CA1CA2 | |
| SCHEMBL30287361 | 0.83 | PTGS2 (0.36) | MEN1KMT2AHTR2ASMN1; SMN2HTR2C | |
| SCHEMBL28996379 | 0.83 | ERN1 (0.41) | MEN1KMT2AHTR2ASMN1; SMN2HTR2C | |
| SCHEMBL30287363 | 0.83 | ERN1 (0.41) | MEN1KMT2AHTR2ASMN1; SMN2HTR2C | |
| SCHEMBL26651006 | 0.83 | PTGS2 (0.36) | MEN1KMT2AHTR2ASMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739684-B | Process for the preparation of 4-methoxypyrrole derivatives | 株式会社大熊制药 | 2024-06-04 | — | — | CN | disclosed |
| US-11858894-B2 | Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-11459297-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-10-04 | — | — | US | disclosed |
| EP-3854784-A1 | METHOD FOR PRODUCING 4-METHOXY PYRROLE DERIVATIVE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-28 | — | — | EP | disclosed |
| US-20210221770-A1 | MANUFACTURING METHOD FOR 4-METHOXYPYRROLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-07-22 | — | — | US | disclosed |
| US-20210221770-A1 | MANUFACTURING METHOD FOR 4-METHOXYPYRROLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-07-22 | — | — | US | disclosed |
| CN-108602771-B | Acid addition salts of compounds | 株式会社大熊制药 | 2021-07-16 | — | — | CN | disclosed |
| CN-108602772-B | Novel crystal form of 1- (5- (2, 4-difluorophenyl) -1- ((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrole-3-yl) -N-methylmelamine salt | 株式会社大熊制药 | 2021-06-04 | — | — | CN | disclosed |
| US-20210139424-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
| US-20190322622-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-10-24 | — | — | US | disclosed |
| US-10336695-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-07-02 | — | — | US | disclosed |
| US-20190047953-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-02-14 | — | — | US | disclosed |
| US-20190031609-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-3433233-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433232-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2019-01-30 | — | — | EP | disclosed |
| EP-3197867-B1 | NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-16 | — | — | US | disclosed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017164576-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-L-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047953-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | MEN1 1926/4885GFER 1990/4885KMT2A 515/4885 |
| US-20210221770-A1 | MANUFACTURING METHOD FOR 4-METHOXYPYRROLE DERIVATIVES | COMT, TH, HPD | MEN1 2718/4885GFER 1494/4885KMT2A 616/4885 |
| US-10336695-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | FIS1, FH, SUCNR1 | MEN1 1616/4885GFER 2162/4885KMT2A 471/4885 |
| US-20210139424-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | MEN1 1926/4885GFER 1990/4885KMT2A 515/4885 |
| US-20190322622-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | MEN1 1926/4885GFER 1990/4885KMT2A 515/4885 |
| US-11459297-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | FIS1, FH, SUCNR1 | MEN1 1616/4885GFER 2162/4885KMT2A 471/4885 |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | MEN1 1926/4885GFER 1990/4885KMT2A 515/4885 |
| US-11858894-B2 | Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt | FIS1, FH, SUCNR1 | MEN1 1616/4885GFER 2162/4885KMT2A 471/4885 |
| US-10100010-B1 | 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | GIPR, GRPR, HTR3E | MEN1 3885/4885GFER 1379/4885KMT2A 3645/4885 |
| US-20190031609-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | PGA5, MIF, JUN | MEN1 2900/4885GFER 1789/4885KMT2A 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.